The electrical and chemical communications taking place in the brain are at such high volumes and on such a microscopic scale, that studying these communications with precision in a live human being can be incredibly difficult. The brain’s biology is also very complex, and when you consider that each individual patient’s wiring varies slightly, it’s obvious that developing efficacious treatments for neurological disorders can be a daunting task.

It takes more money, more time, and more failed attempts to bring a neurological drug to market than it does for any other disease category. Because of the high-risk of investing in neuroscience research, many companies have curtailed or eliminated their spending in this area.

Stevin Zorn, PhD
Lundbeck: Executive Scientist in Residence